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Interval cancers are an important indicator of the quality of a
breast cancer screening programme and a predictor for its success
in reducing breast cancer mortality (Day et al, 1995). The occur-
rence of interval cancers in screening trials and experimental
programmes has been well documented (Tabár et al, 1987; Peeters
et al, 1989; Brekelmans et al, 1992; Moss et al, 1993; Vitak et al,
1997). As routine screening programmes have only started rela-
tively recently, there is still limited information on interval cancers
in such programmes (Woodman et al, 1995; Faux et al, 1997;
Klemi et al, 1997; Sylvester et al, 1997; Boer et al, 1998; Schouten
et al, 1998). First published regional interval cancer rates from the
UK programme were higher than expected and led to some
commotion about the performance of the screening programme
(Woodman et al, 1995).
During 1989–1997 a nationwide breast cancer screening
programme was established in The Netherlands. At the time it was
estimated that it would reduce breast cancer mortality in the total
female population by 17% (Koning et al, 1995b). Early findings
up to 1996 with regard to participation, detection of breast cancers
and stage distribution of screen-detected cancers were rather
favourable, especially in initial screens (Koning et al, 1995a;
Fracheboud et al, 1998). However, the interpretation of the results
was hampered by the lack of information on interval cancers. In
this paper, we present the first national figures on the occurrence
of interval cancers and compare these to regional data from the
UK.
MATERIALS AND METHODS
The Dutch national breast cancer screening
programme
The nationwide breast cancer screening programme started in the
period 1990–1991 in nine screening regions, and at the end of
1993 covered 69% of the target population in The Netherlands.
Details of the programme, offering a biennial screening mammog-
raphy for women aged 50–69 years, are described elsewhere
(Koning et al, 1995a; Fracheboud et al, 1998). In the period
1990–1993, 1.1 million women aged 50–69 had been invited for
screening and 0.84 million women had a screening examination
(attendance rate 76%).
The nine regional screening organizations provide annually a
data set to the National Evaluation Team for Breast cancer
screening (NETB). The NETB aggregates the regional data to
national files for further analysis and comparison with the expecta-
tions based on the cost-effectiveness analysis (Koning et al, 1991).
For evaluation purposes screen examinations were subdivided into
initial and subsequent screens. An initial screen is defined as the
first time the woman is screened within the breast cancer screening
programme; a subsequent screen as a rescreen performed within
2.5 years since the previous screen. Subsequent screens performed
after a longer interval (n = 5357) were excluded from analysis of
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screen-detected and interval cancers. Date of diagnosis of breast
cancer is the day of (diagnostic) biopsy. Reference date of the age
definition is 1 January of the year of screening.
Identifying interval cancers
Interval cancers were identified by linking regional records of
women screened during 1990–1993 to the regional cancer
registries, comparing birth date, first four characters of surname
and postal code in both files. Positive matches were manually
checked to exclude screen-detected cancers of a later screening
round. Due to an inevitable delay in the cancer registry and
because of the screening interval of 2 years, records of women
screened in a certain calendar year (e.g. 1993) cannot be linked to
cancer registry records earlier than in the third year after screening
(thus 1996 or later). Although the national cancer registry has
reached a 100% coverage in The Netherlands since 1989 (NCR,
1992), for technical reasons the linkage procedure was carried out
at regional level. This may lead to some underreporting of interval
cancers in women diagnosed and treated in another region than
where screening took place. The mean national under-reporting is
estimated to be approximately 4%. Furthermore, a small propor-
tion of screened women did not give authorization for record
linkage (0.07% of all screenees).
Within the national evaluation system breast cancers are defined
as epithelial invasive cancers or ductal carcinoma in situ (DCIS) of
the breast. Lobular carcinomata in-situ are regarded as benign
lesion and therefore excluded from analysis. Interval cancers are
breast cancers diagnosed in women after a negative screen
(defined as no recommendation for referral) or after a positive
screen in which assessment did not lead to the diagnosis of cancer,
and before an eventual succeeding screen examination. In case of a
simultaneously diagnosed second breast cancer only the one with
the worst prognosis, and in consecutively diagnosed cases only the
first one is taken into account. Tumour size is classified in accor-
dance with the UICC 1987 guidelines. Percentage distributions of
breast cancer size are based on all breast cancers, including DCIS
(with the exception of Figure 1), Tx tumours and not classified
cancers.
Analysis
Interval cancer data were available nationally for the period
1990–1992 but for 1993, not from one of the nine regions. In
consequence, all data from 1993 from this region were excluded
from the analysis. Follow-up time was calculated from date of last
screen until date of diagnosis of interval cancer, date of next screen
examination or date of eventual death or moving out of the region.
In women with screen-detected cancer, follow-up time was
defined as zero. The observed screen-detected and interval cancer
rates were compared with expected results based on outcomes of
the MISCAN micro simulation model, serving as reference values
for the national evaluation. The model simulates life histories in
the absence of screening and calculates how they change after
introduction of a screening programme depending on the chosen
policy (Oortmarssen et al, 1990; de Koning, 1995a).
The underlying breast cancer incidence and stage distribution
were derived from the first nationally available cancer registry
data from 1989. From these, the data of the central (Utrecht) and
the eastern (Nijmegen) regions were subtracted because they were
influenced by previous screening activities in the 1970s and 1980s.
The resulting population figures served as reference population for
age-adjusting of incidence rates by direct standardization. With
respect to tumour size distribution of interval cancers, data were
not separately available for interval cancers after initial or after
subsequent screens. Breast cancer incidence and stage distribution
in not (yet) screened women for the period 1990–1993 were esti-
mated by subtracting the number of all screened women and the
number of all screen-detected and interval cancers, including
subsequent screens with a longer interval than 2.5 years, from the
total population and incidence, respectively, in the corresponding
period. The category of not (yet) screened women also includes
women with breast cancer from whom it is not known whether
they were screened or not (6% of all breast cancer cases). Age-
adjusted incidence rates of screen-detected cancers, interval
cancers and cancers in not (yet) screened women were related to
the underlying incidence yielding relative incidences (or propor-
tionate incidence with regard to interval cancers).
For the comparison with the North West and East Anglia
regions in the UK screening programme, Dutch results were calcu-
lated for the age group 50–64 years in the same way as described
above. Interval cancers were presented as proportionate incidences
of the underlying incidence in the corresponding programme.
Figures from the East Anglia and North West regions were derived
from published data (Day et al, 1995; Woodman et al, 1995; Boer
et al, 1998). In Figure 1 the analysis had to be restricted to invasive
cancers only because data on DCIS was not available from the
East Anglia programme.
RESULTS
Interval cancer incidence
In 553 501 initially screened women, 3635 breast cancers were
detected, resulting in a detection rate of 6.57 per 1000 screened
women (Table 1). In the first 2 years after screening 1002 interval
cancers (invasive and in situ) were diagnosed, corresponding to an
interval cancer incidence rate of 0.95 per 1000 woman-years of
follow-up. For the 202 782 subsequent screens performed within
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Figure 1 Relative incidences of invasive screen-detected cancers and of
invasive interval cancers (proportionate incidence) in the first and in the
second year after initial screening, The Netherlands and the UK regions
North West and East Anglia, women aged 50–64 years914 J Fracheboud et al
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2.5 years after the previous screen, these rates were 3.46 per 1000
screened women and 0.99 per 1000 woman-years respectively.
This means that of all breast cancers diagnosed in regular partici-
pants 64% will be detected by screening, 36% will emerge as
interval cancers. While detection rates show a clear age-depen-
dency, interval cancer rates do not. Interval cancer rates increased
with time after screening. In subsequent screens, the observed
detection rate was distinctively lower and the interval cancer inci-
dence rate higher than expected.
Relative incidences
Table 2 presents age-adjusted breast cancer incidence rates and
relative incidences of underlying incidence per tumour size,
including DCIS. In 1989, the incidence in the not-screened Dutch
population (underlying incidence) aged 50–69 was 2.32 per 1000.
Initial screening during 1990–1993 led to the detection of almost 
3 times, and subsequent screening to almost 1.5 times, as many
cancers. In the first year after initial screening interval cancers
were found in 27% (26% in subsequent screens) of the underlying
incidence, and in the second year in 52% (55%). In 1990–1993,
almost 12 000 breast cancers were diagnosed in not-screened
women, resulting in an overall incidence rate of 2.45 per 1000,
which is 5% higher than in the not-screened population in 1989. In
situ and small invasive cancers were relatively more often diag-
nosed in this group than in 1989, while large invasive cancers were
reported less frequently.
Tumour size distribution
Table 3 gives the tumour size distribution by different incidence
groups, based on the same numbers of breast cancers as in Table 2.
Table 1 Breast cancer (invasive and in situ) incidence rates, either screen-detected or interval cancers by age per 1000 screened women in 1990–1993
Age Screened Screen-detected Interval cancers (invasive and in situ) per 1000 woman-years follow-up by 6-months period after screening
Years women breast cancers 0–23 < 6 6–11 12–17 18–23 24–29
nn /1000 n /1000 n /1000 n /1000 n /1000 n /1000 n /1000
(After) initial screen
50–54 170 854 718 4.20 323 0.99 28 0.33 100 1.18 85 1.01 110 1.53 26 2.02
55–59 140 194 817 5.83 233 0.87 22 0.32 55 0.79 74 1.07 82 1.38 25 2.48
60–64 134 899 987 7.32 246 0.96 23 0.34 50 0.75 84 1.27 89 1.56 21 2.01
65–69 107 554 1113 10.35 200 0.96 23 0.43 42 0.79 61 1.16 74 1.53 45 1.58
50–69 553 501 3635 6.57 1002 0.95 96 0.35 247 0.90 304 1.12 355 1.50 117 1.89
Expected 6.50 1.00 0.50 0.91 1.22 1.44 1.52
(After) Subsequent screen (performed within 2.5 years since previous screen)
50–54 49 711 120 2.41 81 0.87 10 0.41 18 0.73 38 1.58 15 0.75 8 1.96
55–59 54 101 191 3.53 105 1.04 13 0.48 20 0.75 43 1.65 29 1.34 8 1.88
60–64 57 477 199 3.46 103 0.95 7 0.25 18 0.63 41 1.47 37 1.59 3 0.60
65–69 41 493 191 4.60 88 1.11 12 0.58 23 1.12 25 1.24 28 1.55 12 1.20
50–69 202 782 701 3.46 377 0.99 42 0.42 79 0.79 147 1.50 109 1.31 31 1.33
Expected 4.30 0.96 0.45 0.87 1.19 1.44 1.68
aBased on the outcomes of linkage to the cancer registry in all nine regions 1990–1992 and in eight regions 1993.
Table 2 Age-adjusted breast cancer (invasive and in situ) incidence rates per 1000 women, and relative (proportionate) incidences of underlying incidence by
tumour size, women aged 50–69 years
(Screened)
women Breast cancers Relative (proportionate) incidence
nn per 1000 All DCIS T1a+b T1c T2+
(≤ 10 mm) (11–20 mm) (> 20 mm)
Underlying incidencea 1 208 643 2809 2.32 1 1 1 1 1
Initial screens 1990–1993b
Detection rate 553 501 3639 6.85 2.95 11.80 10.85 3.48 1.05
Interval cancers 1st yearc 553 501 343 0.62 0.27 0.17 0.37 0.35 0.19
Interval cancers 2nd yearc 553 501 659 1.21 0.52 0.33 0.81 0.54 0.44
Subsequent screens 1990–1993b
Detection rate 202 778 712 3.34 1.44 6.19 5.98 1.60 0.49
Interval cancers 1st yearc 202 778 121 0.61 0.26 0.16 0.43 0.35 0.18
Interval cancers 2nd yearc 202 778 256 1.27 0.55 0.34 0.88 0.57 0.45
Breast cancers 1990–1993 4 860 544 11 895 2.45 1.05 1.37 1.22 1.09 0.94
not (yet) screened womenb
aBased on cancer registry data for 1989 from seven regions (two regions with pilot project excluded). b1990–1992: nine regions; 1993: eight regions. 
cData on tumour size distribution not separately available for interval cancers after initial and after subsequent screening.Interval cancers and breast screening in The Netherlands 915
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In not-screened women, about half of all diagnosed cancers were
more than 20 mm in size (T2+). Compared with 1989, breast
cancer diagnosed in not-screened women during 1990–1993
seemed to have shifted towards a more favourable tumour size
distribution, but the higher proportion of Tx-tumours and not-clas-
sified cancers (6.2% vs 2.9%) should be borne in mind. In screen-
detected cancers, more than 75% were DCIS or invasive cancer
not larger than 20 mm in size. The tumour size distribution was
slightly more favourable in subsequent screens. In interval
cancers, the proportion of large invasive cancers was about twice
as high as in screen-detected cancers but still lower than in not-
screened women, especially in the first year after screening. In the
second year after screening the tumour size distribution worsened
and started to look more like that of breast cancers in not-screened
women.
Comparison with UK programme
Figure 1 compares relative incidences of invasive screen-detected
cancers and proportionate incidences of invasive interval cancers
in The Netherlands and the UK regions North West and East
Anglia for initial screens in women aged 50–64 years. The Dutch
programme detected relatively less invasive cancers than the two
UK regions. In the first year after screening, the proportionate
incidence of invasive interval cancers was similar. In the second
year after screening this incidence was clearly lower in the North
West region (48% vs 55%).
Figure 2 presents the per cent tumour size distribution,
including DCIS, for The Netherlands and the North West region.
In the North West, 55% of all detected cancers were in situ carci-
nomas or small invasive cancers ≤ 10 mm against 42% in 
The Netherlands. Whereas first year interval cancers in The
Netherlands showed a slightly more favourable tumour size distri-
bution, in the second year after screening the reverse was the case,
and more than half of the interval cancers were large (T2+).
DISCUSSION
This is the first study with detailed information on interval cancers
from a nationwide breast cancer screening programme. Major
efforts were required of the regional screening organizations and
cancer registries to carry out the linkage procedure and to estimate
the follow-up time of all individual women. This enabled us to
calculate interval cancer rates per woman-years, which is a better
approach than expressing them per number of screened women
(Prior, 1996). Otherwise, not only loss to follow-up due to deaths
and relocations would not be taken into account but also the fact
that in the Dutch programme the average screening interval was
one month shorter than 2 years (Fracheboud et al, 1998).
In the first interval after the initial screen, 1002 interval cancers
(invasive and in-situ), or 0.95 per 1000 woman-years, were diag-
nosed. This was less than expected (1.00 per 1000) but we cannot
exclude a slight under-reporting of interval cancers due to overlap
between the working areas of screening organization and regional
cancer register. An indication for this may be the higher rates
observed in Limburg, one of the Dutch regions where screening
area and regional cancer register completely coincide (Schouten et
al, 1998).
The tumour size distribution of interval cancers was clearly less
favourable than that of screen-detected cancers but more
favourable than in not-screened women, particularly in the first
year after screening. In the second year the proportion of large
invasive tumours > 20 mm increased and the tumour size distribu-
tion started to look more like that in not-screened women. The
figures concerning T2+ tumours in Table 2 and Table 3 show an
annual reduction in the number of advanced cancers of 16%
during the 2-year prevalence screen period and of 44% during an
Table 3 Age-adjusted tumour size distribution (%), women aged 50–69 years
Breast Per cent tumour size distribution
cancers
na Alla DCIS T1a+b T1c T2+ Tx
(≤ 10 mm) (11–20 mm) (> 20 mm) NC
Underlying incidence 2809 100 3.3 7.1 31.6 55.1 2.9
Initial detection 1990–1993 3639 100 13.8 26.3 37.0 19.5 3.4
Subsequent detection 1990–1993 712 100 14.6 29.2 35.4 18.8 2.0
Interval cancers 1st yearb 464 100 2.0 11.5 41.3 39.2 5.8
Interval cancers 2nd yearb 915 100 2.0 11.3 33.2 45.9 7.5
Breast cancers 1990–1993 11 895 100 4.3 8.2 32.4 48.9 6.2
not (yet) screened women
aIncluding Tx tumours and not classified breast cancers (NC). bIncluding both interval cancers after initial screens and interval cancers after subsequent screens
because these data were not separately available.
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Figure 2 Tumour size distribution (including in situ carcinomas) of screen-
detected cancers and interval cancers in the first year and in the second year
after initial screening, the Netherlands (NL) and the North West region (NW),
women aged 50–64 yearsincidence screen cycle. However, the higher proportion of cancers
of unknown tumour size in interval cancers calls for a careful
interpretation, depending on which assumption about the tumour
size distribution of cancers of unknown tumour size is made. If
most of these cancers were advanced tumours, the reduction in
advanced tumours would be less during the described period.
Nevertheless, the observed reduction in the number of advanced
cancers is likely to be an important early indicator of the expected
mortality reduction that is illustrated by the 5% lower breast
cancer mortality in The Netherlands since the start of the
programme (van den Akker-van Marle, 1999).
Because of differences in targeted age groups and/or the lack of
incidence figures, comparison with other screening programmes
had to be limited to regional outcomes of the UK screening
programme. Despite a relatively higher underlying incidence, the
Dutch overall detection rate of 5.73 per 1000 (50–64 years) was
lower than those reported by different UK regions of 5.9–6.7 per
1000 (Woodman et al, 1995; Garvican and Littlejohns, 1996;
Sylvester et al, 1997) or in the nationwide UK programme (Moss
et al, 1995). Compared to the North West region (Figure 2), the
Dutch programme not only detected fewer breast cancers but 
also relatively fewer small invasive cancers. This is somewhat
surprising as in the past, two-view mammography and double
reading have not been used routinely in the UK. Moreover, in the
UK programme microinvasive cancer are usually excluded from
invasive cancers, whereas in The Netherlands they are classified as
small invasive cancer (T1a). With regard to interval cancers, there
were less differences in relative (proportionate) incidences
between the Dutch nationwide programme and the outcomes of
two UK regions. All of them showed substantially higher propor-
tionate incidences than the Swedish Two County Study (Tabár et
al, 1987).
However, the comparisons of relative (proportionate) incidence
should be interpreted with caution. In the Dutch setting breast
cancer in non-attending and non-invited women cannot be identi-
fied separately due to legal limitations. For this reason, the under-
lying incidence is defined as the known incidence before the start
of the screening programme. However, this incidence is based on
historical data of only 1 year (1989, the first year of national
coverage of the National Cancer Registry), and, because of the
exclusion of the two regions where the pilot programmes took
place, not on complete nationwide data. It is therefore difficult to
estimate how the incidence would have developed without a
screening programme (Prior et al, 1996). Even without organized
screening, regional cancer registry data showed an increasing
breast cancer incidence in the late 1980s (Nab et al, 1993). The
slightly higher incidence rate in not (yet) screened women in
1990–1993 compared with 1989 suggests a steady increase of the
underlying incidence. This may be caused by an increasing breast
awareness and a general trend to earlier detection of breast cancer
given the 37% increase of in situ cancers and the 22% increase of
small invasive tumours of ≤10 mm (Table 2).
Nevertheless, efforts to improve the detection of small invasive
cancers should be considered, especially at subsequent screens
because the observed interval cancer rates in subsequent screens
were slightly higher than expected and may be still higher
supposing some underreporting of interval cancers. The Dutch
programme, however, has as a low-referral rate, with only 1%
referrals for further assessment of all women screened during
1990–1996 (NETB, 1997). In the UK programme with reasonably
comparable interval cancer rates, the referral rate was 6%. The
Dutch pilot projects had already tried to find an optimal balance
between too many women unnecessary referred and too few early
cancers detected. The national screening programme adopted this
emphasis on low false-positive rates. Nonetheless, the present
findings suggest that the emphasis should be more on preventing
false-negatives, perhaps at the price of higher referral rates.
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